Aeon Respire is pleased to announce that they’ve completed a pivotal pharmacokinetic (PK) study with inhalation delivery of their lead drug AR-001. Inhaled AR-001 led to 1000 times higher lung exposure than an orally delivered dose of the same drug. Moreover, concentrations of AR-001 in the lung were sustained at or above pharmacologically active levels for many hours. These data validate our reformulation strategy and will be used to inform the design of important upcoming IND-enabling studies needed to advance this new approach to treat respiratory disease.
Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number R44HL156372. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.